Luspatercept for the treatment of anemia in allo-HSCT for patients with hematological diseases - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Luspatercept in the Management of Anemia Following Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Blood Disorders

  • By

  • Xiangke Xin

  • Wenli Zhang

  • Zhen Li

  • Ruirui Gui

  • Juan Wang

  • Liyun Ji

  • Yanli Zhang

  • Baijun Fang

  • Yongping Song

  • Yingling Zu

  • Jian Zhou

  • February 5, 2025

Share

  • 1

    Anemia after allo-HSCT is common and can result from immune or non-immune factors, leading to significant complications.

  • 2

    Luspatercept is the first FDA-approved agent that enhances red blood cell maturation, showing efficacy in treating anemia in specific patient populations.

  • 3

    In a study of 16 patients, luspatercept significantly increased hemoglobin levels, with 81.3% achieving an erythroid response.

  • 4

    The treatment was well-tolerated, with only mild grade 1 toxicities reported and an overall survival rate of 93.8% among patients.

  • 5

    Further research is needed to explore luspatercept's efficacy in treating anemia associated with conditions like PRCA and PGF.

Original Source(s)

Luspatercept for the treatment of anemia in allo-HSCT for patients with hematological diseases

  • by Xiangke Xin, Wenli Zhang, Zhen Li, Ruirui Gui, Juan Wang, Liyun Ji, Yanli Zhang, Baijun Fang, Yongping Song, Yingling Zu, Jian Zhou

  • February 5, 2025

Related Content

Momelotinib in JAK2 inhibitor-naïve myelofibrosis: pros and cons

Impact of Neutropenia on the Effectiveness of Artemisinin-Based Combination Therapy in Pregnant Women in Mali

Clinical Reasoning in Practice: Implementing High-Value Care When Data Discrepancies Arise